Lead Product: INT230-6

Intensity’s lead product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. INT230-6’s three agents are in a fixed ratio. The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. Nonclinical safety studies showed no findings following drug injection into healthy tissues.

Historically physicians administer the two active drugs comprising INT230-6 by intravenous (IV) infusion to achieve a systemic blood level at the limit of tolerability. Unfortunately, dosing drugs IV delivers only a small amount with a low concentration at the tumor site. This approach especially for late stage cancers is not highly effective and often quite toxic to the patient. Past attempts at direct intratumoral injection with chemotherapeutic agents have not shown the ability to treat the injected tumor, non-injected tumors or micro-metastases. This lack of efficacy for local administration is possibly due to poor dispersion and a lack of cell uptake of the agents.  Intensity has solved the problem of dispersion and absorption by adding a novel, tissue dispersing and cell penetrating unique molecule to the formulation.

Due to the use of a novel cell penetration enhancing agent INT230-6 treatment has demonstrated strong efficacy in animals having large tumors and clinical benefit in humans. Our in vivo, nonclinical data shows that INT230-6 thoroughly saturates and kills injected tumors. In addition, the drug induces an adaptive (T-cell mediated) immune response that attacks not only the injected tumor, but non-injected tumors and unseen micro-metastases. Cured animals become permanently immunized against the type of cancer that INT230-6 eliminates. INT230-6 has shown good long-term stability when stored properly.  The drug is now in clinical testing in the U.S and Canada in a Phase 1/2 trial.

Back to Clinical Development
Back to Top